Aurinia raises 2026 revenue outlook to $330 million; shares fall 3.43% premarket
Key Facts
Aurinia Pharmaceuticals reported third-quarter results on October 30 and raised its 2026 revenue outlook to $325–330 million from $315–325 million, but its shares fell 3.43% in premarket trading after the announcement, according to Investing.com. Adjusted earnings per share came in at $0.23, below the analyst consensus of $0.24. Revenue was $83.7 million, compared with an estimate of $84.0 million, despite rising 14% from $73.5 million in the year-earlier quarter. The figures show a contrast between business growth and the company’s higher outlook, and quarterly results and annual guidance that fell short of market estimates. Investing.com reported that the midpoint of the new revenue range, at $327.5 million, was below the analyst consensus of $330.3 million.
Growth in LUPKYNIS sales was the main driver of quarterly revenue, with net sales of the treatment reaching $79.4 million, up 12% from $70.6 million a year earlier. The drug, approved by the U.S. Food and Drug Administration, is used to treat lupus nephritis, according to the company statement published via Nasdaq. For the nine months ended September 30, total revenue reached $244.6 million, up 19% from $205.9 million in the same period of 2025. Third-quarter net income was $31.7 million, compared with $31.6 million a year earlier, while pretax net income rose 21% to $38.7 million from $32.0 million. Cash flow from operating activities was $46.4 million, up 4% from $44.5 million in the third quarter of 2025.
The company raised its full-year total revenue outlook, but the update did not put the midpoint above analyst estimates: it was $327.5 million versus consensus of $330.3 million, according to Investing.com. At the same time, Aurinia narrowed its net product sales outlook to $310–315 million from the previous range of $305–315 million. That means the low end of expected product sales rose, while the high end remained unchanged. Quarterly LUPKYNIS sales, up 12% year over year, provide context for product growth, while total revenue rose 14% year over year in the quarter. The nine-month results reflect a 19% annual increase in revenue to $244.6 million.
Aurinia’s cash, cash equivalents, restricted cash and investments totaled $486.9 million on September 30, 2026, compared with $398.0 million on December 31, 2025. In trading, EL7 data showed the shares closed at $17.21 on October 29, down from $17.36 in the previous session; that close preceded the results announcement issued on October 30. Investing.com reported that the shares ended trading at $17.21 on October 30, and had gained 18.120% over three months and 30.680% over 12 months. These moves place the post-announcement premarket decline in the context of the stock’s performance over preceding periods, without changing the fact that quarterly estimates and the annual revenue consensus were higher than the figures reported by the company. The company reported third-quarter net income of $31.7 million, compared with $31.6 million in the year-earlier period, while pretax income grew 21% year over year.